{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:38:25Z","timestamp":1780569505766,"version":"3.54.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1097\/mnm.0000000000000956","type":"journal-article","created":{"date-parts":[[2018,11,21]],"date-time":"2018-11-21T19:36:59Z","timestamp":1542829019000},"page":"249-257","source":"Crossref","is-referenced-by-count":13,"title":["Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma"],"prefix":"10.1097","volume":"40","author":[{"given":"Conrad-Amadeus","family":"Voltin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Mettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Boellaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Kuhnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Dietlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Drzezga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Kobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-10-20210212","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin\u2019s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"R2-10-20210212","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1056\/NEJMoa1408648","article-title":"Results of a trial of PET-directed therapy for early-stage Hodgkin\u2019s lymphoma","volume":"372","author":"Radford","year":"2015","journal-title":"N Engl J Med"},{"key":"R3-10-20210212","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.2016.68.6394","article-title":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC\/LYSA\/FIL H10 trial","volume":"35","author":"Andr\u00e9","year":"2017","journal-title":"J Clin Oncol"},{"key":"R4-10-20210212","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1080\/10428190903040048","article-title":"Report on the first international workshop on interim-PET-scan in lymphoma","volume":"50","author":"Meignan","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"R5-10-20210212","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2967\/jnumed.112.110890","article-title":"International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers","volume":"54","author":"Biggi","year":"2013","journal-title":"J Nucl Med"},{"key":"R6-10-20210212","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/annonc\/mdp030","article-title":"High SUV uptake on FDG PET\/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDG-PET\/CT staging in lymphoma","volume":"20","author":"Ngeow","year":"2009","journal-title":"Ann Oncol"},{"key":"R7-10-20210212","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1007\/s00259-013-2435-6","article-title":"An international confirmatory study of the prognostic value of early PET\/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and \u0394SUVmax","volume":"40","author":"Itti","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-10-20210212","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2967\/jnumed.113.130609","article-title":"Interim 18F-FDG PET SUVmax reduction is superior to visual analysis in predicting outcome early in hodgkin lymphoma patients","volume":"55","author":"Rossi","year":"2014","journal-title":"J Nucl Med"},{"key":"R9-10-20210212","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00259-014-2715-9","article-title":"qPET - a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma","volume":"41","author":"Hasenclever","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R10-10-20210212","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2017-06-788877","article-title":"Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"key":"R11-10-20210212","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00259-005-1784-1","article-title":"PET\/CT with intravenous contrast can be used for PET attenuation correction in cancer patients","volume":"32","author":"Berthelsen","year":"2005","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-10-20210212","first-page":"283","article-title":"Application of intravenous contrast in PET\/CT: does it really introduce significant attenuation correction error?","volume":"46","author":"Yau","year":"2005","journal-title":"J Nucl Med"},{"key":"R13-10-20210212","doi-asserted-by":"crossref","first-page":"308","DOI":"10.2214\/AJR.04.1740","article-title":"Quantifying the effect of IV contrast media on integrated PET\/CT: clinical evaluation","volume":"186","author":"Mawlawi","year":"2006","journal-title":"Am J Roentgenol"},{"key":"R14-10-20210212","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00259-007-0504-4","article-title":"Does chemotherapy influence the quantification of SUV when contrast-enhanced CT is used in PET\/CT in lymphoma?","volume":"34","author":"Vera","year":"2007","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R15-10-20210212","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.2967\/jnumed.117.190736","article-title":"Test\u2013retest variability in lesion SUV and lesion SUR in 18F-FDG PET: an analysis of data from two prospective multicenter trials","volume":"58","author":"Hofheinz","year":"2017","journal-title":"J Nucl Med"},{"key":"R16-10-20210212","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/MNM.0000000000000086","article-title":"Comparison of liver SUV using unenhanced CT versus contrast-enhanced CT for attenuation correction in 18F-FDG PET\/CT","volume":"35","author":"ter Voert","year":"2014","journal-title":"Nucl Med Commun"},{"key":"R17-10-20210212","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1148\/radiol.2273020299","article-title":"Effects of nonionic intravenous contrast agents at PET\/CT imaging: phantom and canine studies","volume":"227","author":"Nakamoto","year":"2003","journal-title":"Radiology"},{"key":"R18-10-20210212","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"R19-10-20210212","first-page":"1339","article-title":"Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET\/CT scans","volume":"43","author":"Antoch","year":"2002","journal-title":"J Nucl Med"},{"key":"R20-10-20210212","first-page":"567","article-title":"Diagnostic value of CT, PET and combined PET\/CT performed with low-dose unenhanced CT and full-dose enhanced CT in the initial staging of lymphoma","volume":"55","author":"Pinilla","year":"2011","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"R21-10-20210212","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.3109\/10428194.2014.900761","article-title":"Clinical impact of contrast-enhanced computed tomography combined with low-dose 18F-fluorodeoxyglucose positron emission tomography\/computed tomography on routine lymphoma patient management","volume":"55","author":"Chalaye","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"R22-10-20210212","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1182\/blood-2015-11-679407","article-title":"PET-CT for staging and early response: results from the response-adapted therapy in advanced Hodgkin lymphoma study","volume":"127","author":"Barrington","year":"2016","journal-title":"Blood"},{"key":"R23-10-20210212","first-page":"608","article-title":"Effect of reconstruction settings and therapy on 18F-FDG PET\/CT blood pool and liver SUV in patients with diffuse large B-cell lymphoma","volume":"58","author":"van den Belt","year":"2017","journal-title":"J Nucl Med"},{"key":"R24-10-20210212","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s11307-017-1044-3","article-title":"The association between liver and tumor [18F]FDG uptake in patients with diffuse large B cell lymphoma during chemotherapy","volume":"19","author":"Wu","year":"2017","journal-title":"Mol Imaging Biol"},{"key":"R25-10-20210212","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00259-015-3165-8","article-title":"Impact of PET\/CT image reconstruction methods and liver uptake normalization strategies on quantitative image analysis","volume":"43","author":"Kuhnert","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R26-10-20210212","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2967\/jnumed.117.202721","article-title":"Does PET reconstruction method affect Deauville scoring in lymphoma patients?","volume":"59","author":"Enilorac","year":"2018","journal-title":"J Nucl Med"},{"key":"R27-10-20210212","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1007\/s00259-017-3893-z","article-title":"All that glitters is not gold - new reconstruction methods using Deauville criteria for patient reporting","volume":"45","author":"Barrington","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000000956","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:37:55Z","timestamp":1620963475000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006231-201903000-00010"}},"subtitle":["is it significantly affected by contrast-enhanced computed tomography attenuation correction?"],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000000956","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}